DGIdb - ABL1 Gene Record

ABL1 25 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

25
ABL PROTO-ONCOGENE 1, NON-RECEPTOR TYROSINE KINASE
ABL1
ABL
CHDSKM
JTK7
bcr/abl
c-ABL
c-ABL1
p150
v-abl
189980
76
ENSG00000097007
OTTHUMG00000020813
P00519
ABL1_HUMAN
Abelson tyrosine-protein kinase 1
Proto-oncogene c-Abl
Abelson murine leukemia viral oncogene homolog 1
Tyrosine-protein kinase ABL1
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (EC 2.7.1.112) (P150) (C- ABL). [SOURCE:UNIPROT/SWISSPROT;ACC:P00519]
PA24413
4
T63505
BCR-ABL

Gene Info:

Human Readable Name	DRUGGABLE GENOME
Target Class	Enzymes
Target Subclass	EC:2.7.10.2
Uniprot Status	Swiss-Prot
Interpro Short Name	Ser-Thr/Tyr_kinase_cat_dom
Human Readable Name	KINASE
Interpro Name	Serine-threonine/tyrosine-protein kinase catalytic domain
Interpro Acc	IPR001245
Uniprot Evidence	1: Evidence at protein level
Interpro Type	Domain
Target Subclass	2.7.10.2
Target Main Class	Enzymes
Initial Gene Query	ABL
Counted Citations from 1950-2000	7889
Gene Biotype	PROTEIN_CODING

(22 More Sources)

Gene Categories: Category Details

TUMOR SUPPRESSOR
KINASE
TYROSINE KINASE
DRUG RESISTANCE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE

Publications:

Deora et al., Down-modulation of P210bcr/abl induces apoptosis/differentiation in K562 leukemic blast cells., Tumori
Roberts et al., 2014, Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia., N. Engl. J. Med.
Tomita O et al., 2014, Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1., Leuk Res
Testoni et al., 2016, Somatically mutated ABL1 is an actionable and essential NSCLC survival gene., EMBO Mol Med
Jabbour et al., 2008, Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors., Blood
Burgess MR et al., 2005, Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance., Proc Natl Acad Sci U S A
Pemovska T et al., 2015, Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation., Nature
Bradeen HA et al., 2006, Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations., Blood
Müller MC et al., 2009, Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations., Blood
Talpaz M et al., 2006, Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias., N Engl J Med
An et al., 2010, BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review., Leuk. Res.
Strhakova et al., 2011, Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia., Neoplasma
Sharma et al., 2010, Mutations in ABL kinase domain are associated with inferior progression-free survival., Leuk. Lymphoma
Sorel et al., 2004, Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia., Biochem. Biophys. Res. Commun.
Chahardouli et al., 2013, Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib., Hematology
Doi et al., 2009, High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinase domain of the chimerical bcr-abl gene., Int. J. Hematol.
O'Hare et al., 2004, Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML., Blood
Elias et al., 2014, BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome., Leuk. Res.
Qin et al., 2011, Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients., Ann. Hematol.
Hughes et al., 2009, Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase., J. Clin. Oncol.
Al-Ali et al., 2004, High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib., Hematol. J.
MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
Jones et al., 2008, Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors., Cancer
von Bubnoff et al., 2003, Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors., Cancer Res.
von Bubnoff et al., 2002, BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study., Lancet
Branford et al., 2002, High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance., Blood
Eide et al., 2011, The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile., Cancer Res.
Hochhaus et al., 2002, Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy., Leukemia
Soverini et al., 2011, BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet., Blood
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Piccaluga et al., 2007, Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia., Cancer
Deguchi Y et al., 2008, Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines., Leuk Res
Cang et al., 2008, P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia., J Hematol Oncol
Soverini et al., 2006, Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia., J. Clin. Oncol.
Eskazan et al., 2011, Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?, Leuk. Res.
Oyekunle et al., 2011, F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib., Leuk. Res.
Branford et al., 2003, Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis., Blood
Redaelli et al., 2009, Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants., J. Clin. Oncol.
Maekawa et al., 2007, The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias., Int. J. Clin. Oncol.
Weisberg et al., 2006, AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL., Br. J. Cancer
Kantarjian et al., 2007, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance., Blood
Swords et al., 2009, Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib., Drug Des Devel Ther
Rosti et al., 2009, Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia., Blood
Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
Huang et al., 2010, Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant., J. Med. Chem.
Iqbal et al., 2013, Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era., PLoS ONE
Miller et al., 2014, Resistant mutations in CML and Ph(+)ALL - role of ponatinib., Biologics
Tanneeru et al., 2013, Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study., PLoS ONE
Cortes et al., 2012, Ponatinib in refractory Philadelphia chromosome-positive leukemias., N. Engl. J. Med.
Yin et al., 2012, Rapid quantitative detection of the T315I mutation in patients with chronic myelogenous leukemia., Diagn. Mol. Pathol.
Soverini et al., 2011, Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib., Leuk. Res.
Minami et al., 2010, Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment., Int. J. Hematol.
Chahardouli et al., 2013, Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance., Hematology
Paquette et al., 2011, Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors., Cancer Genet
Roche-Lestienne et al., 2002, Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment., Blood
Ferri et al., 2013, Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction., Leuk. Lymphoma
Yamamoto et al., 2004, The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase., Biochem. Biophys. Res. Commun.
Giles et al., 2013, MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia., Leukemia
Elias et al., 2012, Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients., Hematol Rep
Gorre et al., 2001, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification., Science
Hofmann et al., 2002, Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation., Blood
Manrique Arechavaleta et al., 2011, Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors., Clin. Exp. Med.
Agirre et al., 2005, Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib., Cancer Genet. Cytogenet.
Haberler et al., 2006, Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy., J. Neurooncol.
Brueggemeier et al., Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates., Biomacromolecules
Dewar et al., 2005, Inhibition of c-fms by imatinib: expanding the spectrum of treatment., Cell Cycle
Hoerth et al., 2004, Involvment of c-Abl in the radiation-induced inhibition of myoblast differentiation., Int. J. Radiat. Biol.
Mojzych M et al., 2014, Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines., Eur J Med Chem
Page BD et al., 2012, Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity., J Med Chem
Perwein T et al., 2016, Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia., Haematologica
Khoury HJ et al., 2012, Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure., Blood
O'Hare et al., 2005, In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants., Cancer Res.
Nimmanapalli et al., 2002, Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571., Oncogene
Ivan et al., 2006, Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec)., J. Cutan. Pathol.
Adrián FJ et al., 2006, Allosteric inhibitors of Bcr-abl-dependent cell proliferation., Nat Chem Biol
Nehmé et al., 1999, Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells., Br. J. Cancer
Hudkins RL et al., 2012, Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent., J Med Chem
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Dorey et al., 1999, Regulation of human c-Abl tyrosine kinase activity in Xenopus oocytes and acceleration of progesterone-induced G2/M transition by oncogenic forms., Biol. Chem.
Nishimaki et al., 1996, Inhibitory effect of a nucleoside analog, acyclovir, on leukemia cells., Leuk. Res.
Chapman et al., 1994, The suppression of drug-induced apoptosis by activation of v-ABL protein tyrosine kinase., Cancer Res.
Haupt et al., 2006, Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species., Anticancer Drugs
del Senno et al., 1986, Methylation and expression of c-myc and c-abl oncogenes in human leukemic K562 cells before and after treatment with 5-azacytidine., Cancer Detect. Prev.

BOSUTINIB ABL1

Interaction Score: 5.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status NCCN guidelines

PMIDs:
18828913 17114651 21605905 21489624 12623848 21895409 20367437 15381060 23676790 19466505 15256422 24456693 20697894 19652056 14745431 25157968 18615627 14559829 11853795 11964322 21505103 12399961 21562040

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions DoCM COSMIC PharmGKB TTD FDA OncoKB
NILOTINIB ABL1

Interaction Score: 2.85

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name nilotinib , AMN-107,Tasigna

Novel drug target Established target

Variant Effect gain-of-function

PMIDs:
18828913 17114651 21895409 21605905 25157968 20367437 23676790 21489624 12623848 11964322 21562040 19652056 25686603 16772610 19075254 20537386 17929114 16721371 17715389 19920925 19822896 28514312 18191450

Sources:
MyCancerGenome TdgClinicalTrial JAX-CKB TEND DoCM COSMIC CIViC PharmGKB FDA OncoKB
ADENOSINE TRIPHOSPHATE ABL1

Interaction Score: 2.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16415863 11752352 17139284 17016423

Sources:
DTC
PONATINIB ABL1

Interaction Score: 2.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name ponatinib, AP24534

Novel drug target Established target

Clinical Status NCCN guidelines

PMIDs:
20513156 23409026 25349473 24236021 23190221 18828913 17114651 21605905 21489624 22306673 21762985 20963643 12623848 23540562 20537386 21872826 12130516 22870928 15194504 22772060 23355941 11423618 11861307 20512393 21895409 20367437 15381060 23676790 19466505 15256422 24456693 20697894 19652056 14745431 25157968 18615627 14559829 11853795 11964322 21505103 12399961 21562040

Sources:
DTC MyCancerGenome TdgClinicalTrial DoCM CIViC PharmGKB TTD FDA OncoKB
ASCIMINIB ABL1

Interaction Score: 1.9

Interaction Types & Directionality:

allosteric modulator

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions OncoKB
FLUMATINIB ABL1

Interaction Score: 1.9

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
BAFETINIB ABL1

Interaction Score: 0.95

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
18191450

Sources:
MyCancerGenome ChemblInteractions CIViC
NILOTINIB HYDROCHLORIDE MONOHYDRATE ABL1

Interaction Score: 0.95

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CHEMBL483847 ABL1

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16415863

Sources:
DTC
DASATINIB ABL1

Interaction Score: 0.58

Interaction Types & Directionality:

multitarget

inhibitor (inhibitory)

Interaction Info:

Trial Name dasatinib, BMS-354825,Sprycel

Novel drug target Established target

Clinical Status NCCN guidelines

PMIDs:
25207766 24367893 26758680 18818391 15705718 25686603 16772610 19779040 16775234 20537386 21895409 20367437 15381060 23676790 19466505 15256422 24456693 20697894 19652056 14745431 25157968 18615627 14559829 11853795 11964322 21505103 12399961 21562040 17016423 11752352 17701954 18191450

Sources:
MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TEND DoCM COSMIC CIViC PharmGKB FDA OncoKB
IMATINIB ABL1

Interaction Score: 0.5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Fusion protein BCR:ABL1

Trial Name imatinib mesylate, STI 571,Gleevec, Glivec

Novel drug target Established target

PMIDs:
15949566 16205964 16153117 15917650 15799618 24681986 22148584 27125982 25207766 24367893 26758680 22371878 15930265 25686603 12623848 19075254 15194504 20537386 12476305 16630177 18191450 16775234

Sources:
DTC MyCancerGenome TdgClinicalTrial JAX-CKB NCI TEND COSMIC CIViC PharmGKB FDA OncoKB
PONATINIB HYDROCHLORIDE ABL1

Interaction Score: 0.48

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
AZD-0424 ABL1

Interaction Score: 0.48

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
AZM-475271 ABL1

Interaction Score: 0.48

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
REBASTINIB ABL1

Interaction Score: 0.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
ACYCLOVIR ABL1

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8683981

Sources:
NCI
KW-2449 ABL1

Interaction Score: 0.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
CHEMBL219557 ABL1

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
BLINATUMOMAB ABL1

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA
OMACETAXINE MEPESUCCINATE ABL1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
AXITINIB ABL1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25686603

Sources:
CIViC PharmGKB
XL-228 ABL1

Interaction Score: 0.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name XL228

Novel drug target Established target

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions
CEP-11981 ABL1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22148921

Sources:
DTC
AT-9283 ABL1

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions
SARACATINIB ABL1

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
HYDROXYUREA ABL1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7923130

Sources:
NCI
PEXMETINIB ABL1

Interaction Score: 0.14

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name ARRY-614

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
BUSULFAN ABL1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA
MELPHALAN ABL1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7923130

Sources:
NCI
IMATINIB MESYLATE ABL1

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
AZAKENPAULLONE ABL1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MASITINIB ABL1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name masitinib, AB1010

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
AZACITIDINE ABL1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2425967

Sources:
NCI
OXALIPLATIN ABL1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10098743

Sources:
NCI
ENMD-2076 ABL1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ENMD-2076

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
GENISTEIN ABL1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9349317

Sources:
NCI
MLN-8054 ABL1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL406845 ABL1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
REGORAFENIB ABL1

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ADAVOSERTIB ABL1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VINCRISTINE ABL1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA
CELECOXIB ABL1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16917206

Sources:
NCI
CHEMBL546797 ABL1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PROGESTERONE ABL1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10195429

Sources:
NCI
AST-487 ABL1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
QUERCETIN ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9349317

Sources:
NCI
PAZOPANIB ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ALISERTIB ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OSI-632 ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL379975 ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
KENPAULLONE ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ERLOTINIB ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
JNJ-7706621 ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ALSTERPAULLONE ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PD-0166285 ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VANDETANIB ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CENISERTIB ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DTC MyCancerGenome
ENTRECTINIB ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TOZASERTIB ABL1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB ABL1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DOVITINIB ABL1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CYC-116 ABL1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TAE-684 ABL1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ILORASERTIB ABL1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

Ensembl: ENSG00000097007
- Version: 101_38
Alternate Names:

ABL1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TEND: P00519
- Version: 01-August-2011
Alternate Names:

ABL1_HUMAN Uniprot Id

P00519 Uniprot Accession

ENSG00000097007 Ensembl Gene Id

Gene Info:

Target Subclass 2.7.10.2

Target Main Class Enzymes

Publications:
BaderLabGenes: ABL1
- Version: February-2014
Alternate Names:

25 Entrez Gene ID

Gene Info:

Initial Gene Query ABL

Counted Citations from 1950-2000 7889

Gene Categories:

KINASE

Publications:
RussLampel: ENSG00000097007
- Version: 26-July-2011
Alternate Names:

ENSG00000097007 Ensembl Gene Id

ABL1 Display Id

PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (EC 2.7.1.112) (P150) (C- ABL). [SOURCE:UNIPROT/SWISSPROT;ACC:P00519] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:
HopkinsGroom: P00519
- Version: 11-September-2012
Alternate Names:

TYROSINE-PROTEIN KINASE ABL1 Uniprot Protein Name

ENSG00000097007 Ensembl Gene Id

25 Entrez Gene Id

Gene Info:

Uniprot Status Swiss-Prot

Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom

Human Readable Name KINASE

Gene Categories:

KINASE, DRUGGABLE GENOME

Publications:
TdgClinicalTrial: P00519
- Version: January-2014
Alternate Names:

ABL1 Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:2.7.10.2

Publications:

JAX-CKB: ABL1

Version: 27-September-2017

Alternate Names:

25 CKB Entrez Id

ABL1 CKB Gene Synonym

ABL CKB Gene Synonym

Gene Info:

Publications:

Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)

Testoni et al., 2016, Somatically mutated ABL1 is an actionable and essential NSCLC survival gene., EMBO Mol Med

PharmGKB: ABL1
- Version: 18-August-2020
Alternate Names:

PA24413 PharmGKB ID

Gene Info:

Publications:

Pemovska T et al., 2015, Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation., Nature

CIViC: ABL1

Version: 14-September-2020

Alternate Names:

25 Entrez Gene ID

4 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE, CLINICALLY ACTIONABLE

Publications:

Chen Y et al., 2009, Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice., Leukemia

Cortes J et al., 2012, Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation., Blood

Testoni et al., 2016, Somatically mutated ABL1 is an actionable and essential NSCLC survival gene., EMBO Mol Med

NCI: ABL1

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Deora et al., Down-modulation of P210bcr/abl induces apoptosis/differentiation in K562 leukemic blast cells., Tumori

Chapman et al., 1994, The suppression of drug-induced apoptosis by activation of v-ABL protein tyrosine kinase., Cancer Res.

Haupt et al., 2006, Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species., Anticancer Drugs

DoCM: ABL1

Version: 27-September-2017

Alternate Names:

Gene Info:

Publications:

Chahardouli et al., 2013, Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib., Hematology

Branford et al., 2003, Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis., Blood

Sharma et al., 2010, Mutations in ABL kinase domain are associated with inferior progression-free survival., Leuk. Lymphoma

DTC: ABL1

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Adrián FJ et al., 2006, Allosteric inhibitors of Bcr-abl-dependent cell proliferation., Nat Chem Biol

Page BD et al., 2012, Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity., J Med Chem

Mojzych M et al., 2014, Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines., Eur J Med Chem

HingoraniCasas: ENSG00000097007
- Version: 31-May-2017
Alternate Names:

ENSG00000097007 Gene Symbol

ABL1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
MyCancerGenome: ABL1
- Version: 20-Jun-2017
Alternate Names:

25 Entrez Gene Id

ABL1 MyCancerGenome Gene Symbol

ABL MyCancerGenome Reported Gene Name

Gene Info:

Publications:
ChemblInteractions: ABL
- Version: chembl_23
Alternate Names:

JTK7 GENE_SYMBOL

ABL1 GENE_SYMBOL

Tyrosine-protein kinase ABL1 UNIPROT

Gene Info:

Publications:
OncoKB: ABL1
- Version: 23-July-2020
Alternate Names:

p150 OncoKB Gene Synonym

25 OncoKB Entrez Id

v-abl OncoKB Gene Synonym

Gene Info:

Publications:
GO: ABL1
- Version: 01-February-2022
Alternate Names:

ABL GO Gene Synonym

JTK7 GO Gene Synonym

Gene Info:

Gene Categories:

TUMOR SUPPRESSOR, KINASE, TYROSINE KINASE

Publications:
Tempus: ABL1
- Version: 11-November-2018
Alternate Names:

ABL1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
dGene: ABL1
- Version: 27-Jun-2013
Alternate Names:

25 Gene ID

ABL dGene Synonym

JTK7 dGene Synonym

Gene Info:

Gene Categories:

KINASE, TYROSINE KINASE

Publications:
TTD: Tyrosine-protein kinase ABL1
- Version: 2020.06.01
Alternate Names:

ABL TTD Gene Abbreviation

T63505 TTD Target ID

Gene Info:

Publications:
Pharos: ABL1
- Version: 01-February-2022
Alternate Names:

Tyrosine-protein kinase ABL1 Gene Name

P00519 UniProt ID

Gene Info:

Gene Categories:

KINASE

Publications:
MskImpact: ABL1
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FoundationOneGenes: ABL1
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: ABL1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FDA: ABL1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:
COSMIC: ABL1
- Version: 4-Sep-2020
Alternate Names:

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Variant Effect	gain-of-function
Pathway	activation
Clinical Status	NCCN guidelines

Trial Name	nilotinib , AMN-107,Tasigna
Novel drug target	Established target
Variant Effect	gain-of-function

Trial Name	ponatinib, AP24534
Novel drug target	Established target
Clinical Status	NCCN guidelines

Mechanism of Interaction	Tyrosine-protein kinase ABL inhibitor
Direct Interaction	yes

Trial Name	dasatinib, BMS-354825,Sprycel
Novel drug target	Established target
Clinical Status	NCCN guidelines

Fusion protein	BCR:ABL1
Trial Name	imatinib mesylate, STI 571,Gleevec, Glivec
Novel drug target	Established target

Trial Name	XL228
Novel drug target	Established target
Mechanism of Interaction	Tyrosine-protein kinase ABL inhibitor

Trial Name	masitinib, AB1010
Novel drug target	Established target

ABL1_HUMAN	Uniprot Id
P00519	Uniprot Accession
ENSG00000097007	Ensembl Gene Id

TYROSINE-PROTEIN KINASE ABL1	Uniprot Protein Name
ENSG00000097007	Ensembl Gene Id
25	Entrez Gene Id

allosteric modulator
inhibitor (inhibitory)

multitarget
inhibitor (inhibitory)

25	Entrez Gene Id
ABL1	MyCancerGenome Gene Symbol
ABL	MyCancerGenome Reported Gene Name

JTK7	GENE_SYMBOL
ABL1	GENE_SYMBOL
Tyrosine-protein kinase ABL1	UNIPROT

p150	OncoKB Gene Synonym
25	OncoKB Entrez Id
v-abl	OncoKB Gene Synonym

ABL1 Gene Record

ABL1 25 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Variant Effect gain-of-function Pathway activation Clinical Status NCCN guidelines

PMIDs: 18828913 17114651 21605905 21489624 12623848 21895409 20367437 15381060 23676790 19466505 15256422 24456693 20697894 19652056 14745431 25157968 18615627 14559829 11853795 11964322 21505103 12399961 21562040

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions DoCM COSMIC PharmGKB TTD FDA OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name nilotinib , AMN-107,Tasigna Novel drug target Established target Variant Effect gain-of-function

PMIDs: 18828913 17114651 21895409 21605905 25157968 20367437 23676790 21489624 12623848 11964322 21562040 19652056 25686603 16772610 19075254 20537386 17929114 16721371 17715389 19920925 19822896 28514312 18191450

Sources: MyCancerGenome TdgClinicalTrial JAX-CKB TEND DoCM COSMIC CIViC PharmGKB FDA OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 16415863 11752352 17139284 17016423

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name ponatinib, AP24534 Novel drug target Established target Clinical Status NCCN guidelines

Sources: DTC MyCancerGenome TdgClinicalTrial DoCM CIViC PharmGKB TTD FDA OncoKB

Interaction Types & Directionality: allosteric modulator inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor Direct Interaction yes

PMIDs: 18191450

Sources: MyCancerGenome ChemblInteractions CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16415863

Sources: DTC

Interaction Types & Directionality: multitarget inhibitor (inhibitory)

Interaction Info: Trial Name dasatinib, BMS-354825,Sprycel Novel drug target Established target Clinical Status NCCN guidelines

PMIDs: 25207766 24367893 26758680 18818391 15705718 25686603 16772610 19779040 16775234 20537386 21895409 20367437 15381060 23676790 19466505 15256422 24456693 20697894 19652056 14745431 25157968 18615627 14559829 11853795 11964322 21505103 12399961 21562040 17016423 11752352 17701954 18191450

Sources: MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TEND DoCM COSMIC CIViC PharmGKB FDA OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Fusion protein BCR:ABL1 Trial Name imatinib mesylate, STI 571,Gleevec, Glivec Novel drug target Established target

PMIDs: 15949566 16205964 16153117 15917650 15799618 24681986 22148584 27125982 25207766 24367893 26758680 22371878 15930265 25686603 12623848 19075254 15194504 20537386 12476305 16630177 18191450 16775234

Sources: DTC MyCancerGenome TdgClinicalTrial JAX-CKB NCI TEND COSMIC CIViC PharmGKB FDA OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8683981

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info: Fusion protein BCR:ABL1

PMIDs: None found

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status NCCN guidelines

PMIDs:
18828913 17114651 21605905 21489624 12623848 21895409 20367437 15381060 23676790 19466505 15256422 24456693 20697894 19652056 14745431 25157968 18615627 14559829 11853795 11964322 21505103 12399961 21562040

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions DoCM COSMIC PharmGKB TTD FDA OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name nilotinib , AMN-107,Tasigna

Novel drug target Established target

Variant Effect gain-of-function

PMIDs:
18828913 17114651 21895409 21605905 25157968 20367437 23676790 21489624 12623848 11964322 21562040 19652056 25686603 16772610 19075254 20537386 17929114 16721371 17715389 19920925 19822896 28514312 18191450

Sources:
MyCancerGenome TdgClinicalTrial JAX-CKB TEND DoCM COSMIC CIViC PharmGKB FDA OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
16415863 11752352 17139284 17016423

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name ponatinib, AP24534

Novel drug target Established target

Clinical Status NCCN guidelines

Sources:
DTC MyCancerGenome TdgClinicalTrial DoCM CIViC PharmGKB TTD FDA OncoKB

Interaction Types & Directionality:

allosteric modulator

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
18191450

Sources:
MyCancerGenome ChemblInteractions CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
16415863

Sources:
DTC

Interaction Types & Directionality:

multitarget

inhibitor (inhibitory)

Interaction Info:

Trial Name dasatinib, BMS-354825,Sprycel

Novel drug target Established target

Clinical Status NCCN guidelines

PMIDs:
25207766 24367893 26758680 18818391 15705718 25686603 16772610 19779040 16775234 20537386 21895409 20367437 15381060 23676790 19466505 15256422 24456693 20697894 19652056 14745431 25157968 18615627 14559829 11853795 11964322 21505103 12399961 21562040 17016423 11752352 17701954 18191450

Sources:
MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TEND DoCM COSMIC CIViC PharmGKB FDA OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Fusion protein BCR:ABL1

Trial Name imatinib mesylate, STI 571,Gleevec, Glivec

Novel drug target Established target

PMIDs:
15949566 16205964 16153117 15917650 15799618 24681986 22148584 27125982 25207766 24367893 26758680 22371878 15930265 25686603 12623848 19075254 15194504 20537386 12476305 16630177 18191450 16775234

Sources:
DTC MyCancerGenome TdgClinicalTrial JAX-CKB NCI TEND COSMIC CIViC PharmGKB FDA OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
8683981

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25686603

Sources:
CIViC PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name XL228

Novel drug target Established target

Mechanism of Interaction Tyrosine-protein kinase ABL inhibitor

PMIDs:
None found